Skip to main content
Premium Trial:

Request an Annual Quote

HMR Funds Bioinformatics, Cell Research at Harvard

Premium

BOSTON--Harvard Medical School has signed a $16 million, five-year research alliance with the pharmaceutical company Hoechst Marion Roussel involving bioinformatics and cell function. Harvard will receive the funding to study common mechanisms of cell function that have potential applications to human disease, including apoptosis, cell-cycle regulation, and cell regeneration.

The alliance takes effect July 1 and stipulates that Hoechst Marion Roussel will have exclusive first rights to negotiate licenses for patents resulting from the research, and can use nonpatented information at no additional cost. Harvard has the right to publish any information resulting from the alliance. Representatives from Hoechst Marion Roussel and Harvard will cochair a steering committee that will review proposals from Medical School faculty and manage fund allocation.

Filed under

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.